High growth revenue Exagen reported rising quarterly revenue reaching nearly $20M in Q2 2026 and solid Q1 2026 performance with guidance of $70-73M for 2026, signaling expanding market demand for AVISE autoimmune testing solutions.

Strategic partnerships Partnerships with physicians, payers, and biopharma, plus a collaboration with Johns Hopkins on lupus nephritis biomarkers, suggest opportunities to co-market and integrate AVISE tests into payer coverage plans and academic clinical programs.

Clinical leadership Exagen’s unique CB-CAPS, T Cell markers, anti-PAD4 and anti-RA33 tests and leadership in SLE and RA biomarker validation position the company as a preferred vendor for expert rheumatology centers seeking advanced diagnostic platforms.

Rheumatology focus The AVISE platform’s comprehensive rheumatology diagnostics, combined with disease monitoring and prognostic capabilities, aligns with the growing need for early, accurate autoimmune disease management across specialty clinics.

Expansion opportunities With a mid-size enterprise footprint and ongoing leadership hires, there is potential to expand into additional markets, broaden payor coverage, and scale digital/cloud-enabled testing workflows to support broader adoption.